{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:28:54Z","timestamp":1793348934974,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaccao.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:39:05Z","timestamp":1773664745000},"page":"152-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-4808","authenticated-orcid":false,"given":"Osnat","family":"Itzhaki Ben Zadok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrier","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jaccao.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaccao.2026.01.005_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaccao.2026.01.005_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"10.1016\/j.jaccao.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jaccao.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/CIRCULATIONAHA.124.070432","article-title":"Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma and lymphoma undergoing chimeric antigen receptor T-cell therapy","volume":"150","author":"Itzhaki Ben Zadok","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jaccao.2026.01.005_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"41","key":"10.1016\/j.jaccao.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jaccao.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jaccao.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jaccao.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.jaccao.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"10.1016\/j.jaccao.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.jaccao.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:31:27Z","timestamp":1786404687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666087326000487"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.01.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}